Aptevo reports Q3 results, mipletamig AML trial data

Aptevo Therapeutics (APVO) reported a Q3 2026 net loss of $6.5M, down from $7.5M in Q3 2025. Cash reserves fell to $8.3M. The company shared positive clinical data for mipletamig in AML treatment, with 79% remission rate in a small trial. It aims to complete Phase 1b trials by year-end and plans regulatory interaction in early 2027. Aptevo raised $4.5M in August via warrant inducement and private placement.

Original reporting
Published Nov 16, 2026, 1:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$APVO
Bullish
high confidence
Mentioned
$APVO
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$APVOBullishHigh
01

Why it matters

The remission rate of 79% in TP53‑mutated AML patients exceeds historical benchmarks, suggesting a differentiated therapeutic profile that could attract partnership interest or boost valuation.

02

Market read

First‑time disclosure of strong early‑phase data for a niche AML therapy, likely to move APVO stock in the short term.

03

What to watch

Potential regulatory timeline and need for larger Phase 2/3 data could temper upside.

Relevance 8/10Novelty 8/10Timing: immediate reaction today

Background

Aptevo Therapeutics (NASDAQ:APVO) is a clinical‑stage biotech focused on AML therapies. The company disclosed Q3 financials and early trial outcomes.

Company-level read

Ticker impact

$APVOBullishHigh confidence
Context

Aptevo Therapeutics reported Q3 loss and disclosed strong Phase 1b AML trial results with 79% remission rate, a first‑time disclosure.

Expected impact

upward pressure as market prices in the high remission rate versus historical benchmarks

Evidence & confidence

First report of compelling efficacy data for a micro‑cap biotech typically triggers a rapid price move.

Market effects

May boost sentiment for AML and TP53‑mutated AML therapeutic space.

Limited to US biotech investors; no broader regional effect.

Minor global impact, confined to specialty biotech niche.

Counterpoint

Skeptics may question durability of early‑phase data and small sample size.

Key entities

  • Aptevo Therapeutics Inc.

    US‑listed biotech reporting Q3 results and trial data.

  • mipletamig

    Investigational AML therapy evaluated in the RAINIER trial.

Related articles

$APVOHighAI 8/10

Aptevo 3Q 2026: EPS ($5.19) — 10-Q Summary

Aptevo reported a wider net loss for 3Q 2026, driven by a $2.8M deemed dividend and lower expenses. EPS loss narrowed to $5.19 vs. $40.13 YoY. Clinical progress includes 79% CR/CRi rate in AML patients and Phase 1b completion targeted for 2026. APVO451 received a $1.5M grant for IND-enabling studies.

$APVOMedAI 8/10

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibits 99.1 Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmark Ten of 47 patients re

$APVOMedAI 8/10

Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity—offering potential for difficult-